GLI-Kruppel family member Gli1 is a transcriptional activator, which is part of the Gli family of transcription factors. It is a target of hedgehog signaling.
Immunogen
Synthetic peptide containing a sequence corresponding to a region within amino acids 755 and 810 of Gli1 according to NP_034426
Application
Suggested starting dilutions are as follows: WB: 1:500-1:3000. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.
Biochem/physiol Actions
GLI-Kruppel family member Gli1 may regulate the transcription of specific genes during normal development. It may also play a role in osteoblast formation, craniofacial development and digital development, as well as development of the central nervous system and gastrointestinal tract. The protein mediates SHH signaling and thus cell proliferation and differentiation. Gli1 may also be involved in tissue repair in pancreas. This protein has a protective role during stroke, ischemic injury and Parkinson′s disease.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
1XPBS, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Medulloblastoma (MB) is a malignant pediatric brain tumor that arises in the cerebellar granular neurons. Sonic Hedgehog subtype of MB (SHH-MB) is one of the major subtypes of MB in the clinic. However, the molecular mechanisms underlying MB tumorigenesis are
Chronic myeloid leukemia (CML) patients with complex chromosomal translocations as well as non-compliant CML patients often demonstrate short-lived responses and poor outcomes on the current therapeutic regimes using Imatinib and its variants. It has been derived so far that leukemic
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.